Document:

EX-10.8.C

EXHIBIT 10.8(c)

	 	 	 
	To:

	 	Dr. Ronald Warner
	 
	 	 
	From:

	 	Dean Mitchell
	 
	 	 
	Regarding:

	 	Employment Terms
	 
	 	 
	Date:

	 	September 1, 2008

This memo confirms your employment as Executive Vice President and Chief Scientific Officer of
Alpharma Inc. (“Alpharma” or the “Company”), reporting to me.

The terms of your employment are listed below and in the plan documents for each of the
compensation and benefits programs available to you. (In the event of any inconsistency between
this memo and the plan documents, as may be amended from time to time, the plan documents will
govern).

Effective Date: September 1, 2008.

Annual Base Salary: Your annual base salary shall continue at your current rate of
$441,000/year.

Executive Allowance: Your executive allowance will remain at $28,600 per year, paid
bi-weekly.

Short Term Incentive Plan (STIP): Your target bonus will remain at 50% of your base
salary.

Severance Plan and Change of Control Plan:

You will be eligible for benefits under Alpharma’s Severance and Change of Control Plans (the
“Plans”) as a member of my Leadership Team. Subject to all of the terms of the Plans and
applicable laws: (a) the Severance Plan provides for 18 months of base salary and bonus should your
employment be terminated by the Company for any reason other than “for Cause” (as such term is
defined therein); and (b) the Change of Control Plan provides for an additional 12 months of base
salary and bonus (30 months total) should certain changes to the Company’s ownership structure
occur and, during the two-year period following such change, you are subject to an Involuntary
Termination or Constructive Termination (as such terms are defined therein). Please consult the
Plans for a description of other benefits to be provided to you in the event of a covered
termination of your employment.

Life and Accident Insurance Benefits:

Your Basic Life Insurance and your Basic Accidental Death & Dismemberment Insurance coverages will
continue at three times your base annual salary, rounded to the next highest $1,000. The maximum
benefit for each of these insurance coverages is $1,000,000. For complete details, please visit
www.alpharma.com/benefits.

Other Benefits:

You will be provided with an annual paid vacation of 20 days per calendar year, accrued in
accordance with our vacation policy. You will also continue to be given 12 holidays each calendar
year (4 of which were

 

 

designated as floating holidays in 2008). All vacation days and floating holidays must be taken
in accordance with the Company’s vacation policy, as is in effect from time to time.

Entire Agreement:

You acknowledge and agree that this memo sets forth your compensation in full, and there are no
other agreements, arrangements or commitments regarding your compensation or employment that are
not superseded by this memo, with the exception of: (a) the Company’s health and benefit plans that
are available to all employees at your level, (b) any confidentiality and assignment of
intellectual property undertakings signed by you, and (c) that certain letter agreement between you
and the Company dated January 3, 2008 regarding certain health benefits, which is attached hereto
as Exhibit A, and which is hereby amended as set forth on Exhibit A. For the avoidance of
doubt, you acknowledge and agree that the following employment-related agreements between you and
the Company are hereby terminated and of no further force or effect: Agreement dated November 6,
2002, Agreement dated February 26, 2003 and Agreement dated December 12, 2005.

At-Will Employment / Confidentiality:

Please note that this memo is not a promise or offer of continued employment by the Company, and
does not change the “at will” status of your employment with Alpharma. We also remind you that the
confidentiality and assignment of intellectual property undertakings you executed when you joined
Alpharma remain in full force and effect.

On behalf of the Leadership Team, I would like to thank you for all of your dedication and hard
work. We look forward to your continued contributions at Alpharma. Please execute below to
acknowledge and accept the terms of your position, and return your signed acceptance to me.

Sincerely,

	 	 	 	 	 
	/s/ Dean Mitchell	 	 
	 	 	 
	Dean Mitchell	 	 
	 
	 	 	 	 
	/s/ Ronald Warner	 	 
	 	 	 
	Name:

	 	Dr. Ronald Warner	 	 
	Date:

	 	September 1, 2008	 	 

 

 

Exhibit A

See Attached Letter Agreement dated January 3, 2008

The reference in the attached Letter Agreement dated
January 3, 2008 to the "’Special
Severance Arrangement’ contained in the letter agreement between you and the Company, dated
December 12, 2005” shall instead refer to the benefits available to you under the Company’s
Severance Plan or Change in Control Plan.

 

 

January 3, 2008

Dr. Ronald N. Warner

349 Grandview Road

Skillman, NJ 08558

Dear Ron:

     By this letter Alpharma Inc. (the “Company”) desires to clarify for you the Company’s general
policy, and by this letter obligate the Company to follow the this general policy as set forth
below, with respect to the termination of coverage for you and your dependants under the Company’s
Medical Plan (the “Medical Plan”):

	 	 	If you cease being an active employee due to an Injury or Sickness (as those terms are
defined in the Medical Plan), your medical insurance will be continued (upon the same terms
and conditions then generally applicable to active employees of the Company or its successor)
for a maximum of 30 months while you remain eligible to participate in either the Short Term
or Long Term Disability Plans of the Company as a result of the same Injury or Sickness that
caused you to cease being an active employee. However, this coverage shall not continue past
the date the Company or its successor cancels its Medical Plan and any successor plan or
plans as it applies generally to its employees or the employees of any successor to the
company.
	 
	 	 	In the event of a cessation of active employment after which you are entitled to continue to
participate in the Medical Plan (or any successor plan or plans), which specifically includes
a cessation of employment under the terms of the preceding paragraph or pursuant to the terms
of the “Special Severance Arrangement” contained in the letter agreement between you and the
Company, dated December 12, 2005, the “qualifying event” for purposes of your ability to
elect COBRA continuation coverage under the Medical Plan (or any successor plan or plans)
will be the cessation of your participation in the Medical Plan (or any successor plan or
plans) and at such time you will be able to continue your coverage under the Medical Plan (or
any successor plan or plans) pursuant to COBRA.

     This letter, and the obligations set forth herein, shall be binding upon, and inure to the
benefit of, the parties hereto, any successors or assigns of the Company and your heirs or personal
representatives. If the Company consolidates with or merges into or sells all or substantially all
of its assets to another corporation, partnership or other entity or person, the successor
corporation, partnership or other entity or person shall become obligated to perform all of the
terms and conditions set forth herein.

     This letter shall not alter or effect the other provisions of your employment as presently in
effect.

     This letter may not be modified, amended or waived in any manner except by an instrument in
writing signed by both you and the Company. The terms of this letter shall governed by and
construed in accordance with New Jersey law (regardless of the laws that might otherwise govern
under applicable New Jersey principles of conflicts of law).

	 	 	 	 	 
	 	 	Very truly yours,
	 
	 	 	 	 
	 	 	Alpharma Inc.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Peter WattsEX-10.9.D

Exhibit 10.9(d)

	 	 	 
	To:

	 	Carol A. Wrenn
	 
	 	 
	From:

	 	Dean Mitchell
	 
	 	 
	Regarding:

	 	Employment Terms
	 
	 	 
	Date:

	 	September 1, 2008

This memo confirms your employment as President, Animal Health of Alpharma Inc. (“Alpharma” or the
“Company”), reporting to me.

The terms of your employment are listed below and in the plan documents for each of the
compensation and benefits programs available to you. (In the event of any inconsistency between
this memo and the plan documents, as may be amended from time to time, the plan documents will
govern).

Effective Date: September 1, 2008.

Annual Base Salary: Your annual base salary shall continue at your current rate of
$414,000/year.

Executive Allowance: Your executive allowance will remain at $28,600 per year, paid
bi-weekly.

Short Term Incentive Plan (STIP): Your target bonus will remain at 50% of your base
salary.

Severance Plan and Change of Control Plan:

You will be eligible for benefits under Alpharma’s Severance and Change of Control Plans (the
“Plans”) as a member of my Leadership Team. Subject to all of the terms of the Plans and
applicable laws: (a) the Severance Plan provides for 18 months of base salary and bonus should your
employment be terminated by the Company for any reason other than “for Cause” (as such term is
defined therein); and (b) the Change of Control Plan provides for an additional 12 months of base
salary and bonus (30 months total) should certain changes to the Company’s ownership structure
occur and, during the two-year period following such change, you are subject to an Involuntary
Termination or Constructive Termination (as such terms are defined therein). Please consult the
Plans for a description of other benefits to be provided to you in the event of a covered
termination of your employment.

Life and Accident Insurance Benefits:

Your Basic Life Insurance and your Basic Accidental Death & Dismemberment Insurance coverages will
continue at three times your base annual salary, rounded to the next highest $1,000. The maximum
benefit for each of these insurance coverages is $1,000,000. For complete details, please visit
www.alpharma.com/benefits.

Other Benefits:

You will be provided with an annual paid vacation of 20 days per calendar year, accrued in
accordance with our vacation policy. You will also continue to be given 12 holidays each calendar
year (4 of which were

 

 

September 1, 2008

Page 2

designated as floating holidays in 2008). All vacation days and floating
holidays must be taken in accordance with the Company’s vacation policy, as is in effect from time
to time.

Entire Agreement:

You acknowledge and agree that this memo sets forth your compensation in full, and there are no
other agreements, arrangements or commitments regarding your compensation or employment that are
not superseded by this memo, with the exception of: (a) the Company’s health and benefit plans that
are available to all employees at your level, and (b) any confidentiality and assignment of
intellectual property rights undertakings signed by you. For the avoidance of doubt, you
acknowledge and agree that the following employment-related agreements between you and the Company
are hereby terminated and of no further force or effect: Agreement dated October 19, 2001,
Agreement dated July 15, 2003, Agreement dated February 11, 2004 and Agreement dated December 19,
2005.

At-Will Employment / Confidentiality:

Please note that this memo is not a promise or offer of continued employment by the Company, and
does not change the “at will” status of your employment with Alpharma. We also remind you that the
confidentiality and assignment of intellectual property rights undertakings you executed when you
joined Alpharma remain in full force and effect.

On behalf of the Leadership Team, I would like to thank you for all of your dedication and hard
work. We look forward to your continued contributions at Alpharma. Please execute below to
acknowledge and accept the terms of your position, and return your signed acceptance to me.

	 	 	 	 	 
	Sincerely,	 	 
	 
	 	 	 	 
	/s/ Dean Mitchell	 	 
	 	 	 
	Dean Mitchell	 	 
	 
	 	 	 	 
	/s/ Carol A. Wrenn	 	 
	 	 	 
	Name:

	 	Carol A. Wrenn	 	 
	Date:

	 	September 1, 2008

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]